Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$8.81MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adam R. Craig
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 45
- Beta
- 0.35
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.90
Financials
Revenue
$8.81M+193.5%Net Income
$-16.16MEBITDA
$-12.77MFree Cash Flow
$-40.39MEPS (diluted)
$-0.13Shares Outstanding (diluted)
126.34M+31719.4%Operating Expenses
$23.58MCash & Debt
$207.97MReturn of Capital
$0.00Revenue by Segment (annual)
$35.11MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $35.11M | $-79.20M | $-1.87 |
| 2024 | $2.56M | $-37.45M | $-5.59 |
| 2023 | $0.00 | $-101.17M | $-17.07 |
| 2022 | $0.00 | $-93.87M | $-45.60 |
| 2021 | $0.00 | $-88.70M | $-119.58 |
| 2020 | $3.00M | $-62.13M | $-92.84 |
| 2019 | $0.00 | $-52.81M | $-138.94 |
| 2018 | $0.00 | $-33.28M | $-14238.00 |
| 2017 | $0.00 | $-33.88M | $-17767.00 |
| 2016 | $0.00 | $-22.98M | $-1737.74 |
| 2015 | $0.00 | $-13.22M | $-1266.46 |
Valuation
XFORhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
104-17.89%Social Signal Score
Mentions (4)
- Newszacks.com·11d ago·Neutral
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·24d ago·Neutral
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET.
View source ↗ - Newszacks.com·55d ago·Positive
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.18 per share
Typical surprise +23.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.13 vs $-0.18beat
- Wed, May 6$-0.16 vs $-0.20beat
- Tue, Mar 17$-0.22 vs $-0.36beat
- Wed, Nov 5$-0.69 vs $-0.79beat
- Fri, Aug 8$-3.47 vs $-4.53beat
- Thu, May 1$0.04 vs $-4.13beat
Estimates and results for XFOR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XFOR officers and directors.
- Bought
- $272k
- Sold
- $1.5m
4 trades
31 trades
- Volpone Johnsold
- Craig Adam Rsold
- Kirske Davidsold
- Kirske Davidsold
- Craig Adam Rbought
- Baldry Markbought
- Ragan Paulasold
- Mostafa Adam S.sold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XFOR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.